CN87104870A - Benzoxazinnorifamyciderivative derivative, its preparation method that alkyl replaces and contain the antiseptic-germicide of this derivative - Google Patents
Benzoxazinnorifamyciderivative derivative, its preparation method that alkyl replaces and contain the antiseptic-germicide of this derivative Download PDFInfo
- Publication number
- CN87104870A CN87104870A CN87104870.1A CN87104870A CN87104870A CN 87104870 A CN87104870 A CN 87104870A CN 87104870 A CN87104870 A CN 87104870A CN 87104870 A CN87104870 A CN 87104870A
- Authority
- CN
- China
- Prior art keywords
- derivative
- carbon atom
- gram
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of new Ryfamycin derivative [formula (I)] or its salt, its preparation method and with its antiseptic-germicide as effective constituent.Said derivative has strong anti-microbial activity for gram positive organism and aciduric bacteria.In formula (I), X
1Be C
1-C
6Alkyl or C
3-C
8Cycloalkyl; X
2Be hydrogen or C
1-C
4Alkyl; R
1Be hydrogen or ethanoyl; A is a group
Or
R wherein
2Be C
1-C
4Alkyl or C
2-C
6Alkoxyalkyl, R
3Be C
1-C
6Alkyl or C
2-C
6Alkoxyalkyl, N are C
2-C
8Ternary to nonatomic ring amido, R
4Be hydrogen or C
1-C
4Alkyl.
Description
The present invention relates to Ryfamycin derivative or its salt, its preparation method of a class novelty and contain the antiseptic-germicide of this derivative as effective constituent.Particularly, the present invention relates to have the formula I structure a kind of novelty Ryfamycin derivative or its salt, its preparation method and contain the antiseptic-germicide of this derivative as effective constituent; Said formula I is:
In the formula: X
1Be the cycloalkyl of the alkyl or 3-8 the carbon atom of 1-6 carbon atom,
X
2Be the alkyl of a hydrogen atom or 1-4 carbon atom,
R
1Be hydrogen atom or ethanoyl,
A is by formula:
A group of representative, wherein:
R
2Be the alkyl of 1-4 carbon atom or the alkoxyalkyl of 2-6 carbon atom, and
R
3Be the alkyl of 1-6 carbon atom or the alkoxyalkyl of 2-6 carbon atom,
Be the 3-9 unit cyclammonium base of 2-8 carbon atom of band, R
4It is the alkyl of a hydrogen atom or 1-4 carbon atom.
In the present invention, by formula
3-9 unit representative, 2-8 carbon atom of band cyclammonium base is meant the group by the following formula representative:
Ryfamycin derivative of the present invention is a class new compound of not reporting as yet in the document.
The invention provides the class with formula I structure novel Ryfamycin derivative or its salt, its manufacture method and contain the antiseptic-germicide of this derivative as effective constituent; Said formula I is:
X in the formula
1Be the cycloalkyl of the alkyl or 3-8 the carbon atom of 1-6 carbon atom,
X
2Be the alkyl of a hydrogen atom or 1-4 carbon atom,
R
1Be hydrogen atom or ethanoyl,
A is by formula:
The group of representative, wherein
R
2Be the alkyl of 1-4 carbon atom or the alkoxyalkyl of 2-6 carbon atom, and
R
3Be the alkyl of 1-6 carbon atom or the alkoxyalkyl of 2-6 carbon atom,
R
4It is the alkyl of a hydrogen atom or 1-4 carbon atom.
The inventor discovers that the Ryfamycin derivative with formula I structure can make with following method, is about to have the amine reaction of the Ryfamycin derivative and the formula AH of formula II structure; Said formula I is:
X wherein
1, X
2, R
1The same with the A definition, said formula II is:
X wherein
1, X
2And R
1Define the same.A definition among the said formula AH is the same.It is strong that the Ryfamycin derivative with formula I structure that makes like this presents anti-microbial activity.
Ryfamycin derivative with formula I structure can be dissolved among the various organic solvents, for example ethers such as aromatic hydrocarbons such as ester class, benzene such as alcohols such as halogenated hydrocarbon, ethanol, ethyl acetate such as chloroform and tetrahydrofuran (THF).
Substituent X with novel rifomycin of formula I structure of the present invention
1And X
2Example have:
X with alkyl of 1-6 carbon atom
1Example has: methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, sec-butyl, the tertiary butyl, amyl group, isopentyl, neo-pentyl, tert-pentyl, 1-methyl butyl, 2-ethyl-butyl, hexyl, isohexyl, uncle's hexyl, 1-methyl amyl, 1-ethyl-butyl etc.
X with cycloalkyl of 3-8 carbon atom
1Example have: cyclopropyl, 1-methyl cyclopropyl, 2-methyl cyclopropyl, 1-ethyl cyclopropyl, 2-ethyl cyclopropyl, 1-propyl group cyclopropyl, 2-propyl group cyclopropyl, 2,2-dimethyl cyclopropyl, 2,3-dimethyl cyclopropyl, cyclobutyl, 1-methyl cyclobutyl, 2-methyl cyclobutyl, 3-methyl cyclobutyl, 1-ethyl cyclobutyl, 2-ethyl cyclobutyl, 3-ethyl cyclobutyl, 1-propyl group cyclobutyl, 2-propyl group cyclobutyl, 3-sec.-propyl cyclobutyl, 2, the 2-dimethylcyclobutyl, 3, the 3-dimethylcyclobutyl, cyclopentyl, the 1-methylcyclopentyl, the 2-methylcyclopentyl, the 3-methylcyclopentyl, 1-ethyl cyclopentyl, 2-ethyl cyclopentyl, 3-ethyl cyclopentyl, 1-propyl group cyclopentyl, 2-propyl group cyclopentyl, 3-sec.-propyl cyclopentyl, 2, the 3-dimethylcyclopentyl, cyclohexyl, the 1-methylcyclohexyl, the 2-methylcyclohexyl, the 3-methylcyclohexyl, the 4-methylcyclohexyl, 1-ethyl cyclohexyl, 2-ethyl cyclohexyl, 3-ethyl cyclohexyl, 4-ethyl cyclohexyl, 2, the 2-Dimethylcyclohexyl, 2, the 3-Dimethylcyclohexyl, 4, the 4-Dimethylcyclohexyl, 3, the 5-Dimethylcyclohexyl, suberyl, 1-methyl suberyl, 2-methyl suberyl, 3-methyl suberyl, 4-methyl suberyl, ring octyl group etc.
The X that contains the alkyl of 1-5 carbon atom
2Example has methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, sec-butyl, the tertiary butyl, amyl group, isopentyl, neo-pentyl, tert-pentyl, 1-methyl butyl etc.
Ryfamycin derivative of the present invention with formula I structure may also can form salt with alkali with acid.Can use with salifiable any alkali of formula I Ryfamycin derivative shape or acid.The salt that forms with alkali is for example: (1) metal-salt, particularly an alkali metal salt or alkaline earth salt, (2) ammonium salt and (3) amine salt, the particularly salt that generates with methylamine, ethamine, diethylamine, triethylamine, tetramethyleneimine, morpholine or hexamethylene imine.
The salt that forms with acid is as salt that (1) and mineral acids such as sulfuric acid or hydrochloric acid form, and the salt that forms of (2) and organic acids such as tosic acid, trifluoroacetic acid or acetate.
Available following method prepares the Ryfamycin derivative of the present invention of formula I structure:
(a) preparation method of Ryfamycin derivative of the present invention is, in the oxygenant existence or not, in all example hydrochloric acids and so on acid existence or not,-20 ℃ to organic solvent (as methyl alcohol, ethanol, tetrafluoro furans, N, dinethylformamide or dimethyl alum) between the boiling point under certain temperature, after being dissolved in Ryfamycin derivative (II) in the said solvent, the same with AH(H definition again) amine reaction 1 hour to 1 month.
Ryfamycin derivative (II) (being a kind of raw material) can prepare according to the compound of described methods such as W.Kump (Helv.Chim.Acta, 56,2348, (1978)) with rifamycin-S and following formula representative:
X wherein
1And X
2Define the same.
The example of the reaction solvent that the present invention uses, for example methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), pyridine, acetone, ethyl acetate, chloroform, N, dinethylformamide, dimethyl alum etc.Pyridine wherein, N, dinethylformamide or dimethyl alum are preferentially to select for use among the present invention, its result is fabulous.
Under-20 ℃ of certain temperature between the said solvent boiling point, be preferably under-5 ℃ to 50 ℃ and carry out this reaction.
Though this reaction can be carried out about 1 hour to about 1 month, the time in the time of should determining optimum response according to reaction process.Because reaction process because of amine kind and the quantity used among the present invention, whether have oxygenant, if present, condition such as the oxygenant kind that exists and quantity and temperature of reaction and changing is so said reaction process can illustrate by tlc or other method.
So be reflected at when carrying out under the oxygenant existence, use air, oxygen, Manganse Dioxide, plumbic oxide, silver suboxide, the Tripotassium iron hexacyanide, hydrogen peroxide etc. as oxygenant.The present invention preferentially selects wherein Manganse Dioxide, silver suboxide, Tripotassium iron hexacyanide etc. for use, and it is dry straight.
(b) also available following method prepares Ryfamycin derivative of the present invention (I): by the operation steps described in above-mentioned (a), but replace the Ryfamycin derivative (II) in (a) to make raw material with Ryfamycin derivative (III).
Wherein: R
1, X
1And X
2Define the same, X
3Be halogen atom, lower alkoxy or nitro.
The method (Helv.Chim.Acta, 56,2348, (1978)) that Ryfamycin derivative (III) (being a kind of raw material) can be introduced according to people such as W.Kump, the compound of representing with rifamycin-S and following formula reacts and prepares:
Wherein, X
1, X
2And X
3Definition as above.
(c) R wherein
1The Ryfamycin derivative I that is hydrogen atom also can make Ryfamycin derivative (I) (R wherein with acid or alkali
1Be ethanoyl) preparation of the method for hydrolysis.The acid that hydrolysis is used is as organic acids such as: mineral acids such as (1) sulfuric acid or hydrochloric acid and (2) tosic acid or trifluoroacetic acids.The alkali that hydrolysis is used is as alkali metal hydroxides such as (1) sodium hydroxide or potassium hydroxide, (2) alkaline earth metal hydroxides such as calcium hydroxide or hydrated barta, and (3) are such as 1,5-diazabicyclo (4,3,0) nonene (5) or 1,8-diazabicyclo (5,4,0) undecylene organic basess such as (7).
Said hydrolysis reaction preferably at room temperature adopts alkalimetal oxide such as sodium hydroxide or potassium hydroxide and uses in the solvent such as aqueous methanol or aqueous pyridine and carry out.
Ryfamycin derivative of the present invention (I) is the intense violet color solid, can from reaction product, be separated and purifying with quite being easy to method, promptly from reaction system, remove excessive amine AH(A definition as above) and reaction solvent after just obtain crude product, then with purifying in addition such as crystallization or column chromatography.
Also can good fortune adm derivative (I) also originally be transformed into Ryfamycin derivative (IV) with (I) with reductive agents such as xitix or sodium bisulfites:
X wherein
1, X
2, R
1The same with the definition of A.Ryfamycin derivative (IV) also is a kind of new compound, and demonstrates strong anti-microbial activity.
Typical Ryfamycin derivative of the present invention is listed among the table 1.
In table 1, infrared absorption spectrum is that sample is ground into fine powder with Potassium Bromide, is pressed into that little cake measures again; Thin-layer chromatography is to adopt silica gel 60F
254(E.Merck company makes plate, carries out under the condition of 20cm * 20cm); Nuclear magnetic resonance spectrum is adopting tetramethylsilane to do to measure under the conditions such as reference material and full deuteriochloroform solution.
Ryfamycin derivative of the present invention presents gram-positive microorganism and aciduric bacteria the strong antibiotic effect.Can standard method (Chemotherapy(Tokyo) according to Japanese chemotherapy, 29,76, (1981)), tested the anti-microbial effect of Ryfamycin derivative of the present invention.Record by more said exemplary compounds that the results are shown in Table 2.As shown in table 2, clearly showing Ryfamycin derivative of the present invention has the strong antibiotic effect for gram positive organism and aciduric bacteria.Test compound in table 2 number is equivalent to the derivative number in the table 1.
Find that also Ryfamycin derivative toxicity of the present invention is little, because give the mouse oral administration, 1000 milligrams of per kilogram of body weight consumptions heavily do not present toxicity behind the listed Ryfamycin derivative of the present invention in the table 1.
The Ryfamycin derivative of the present invention of formula I absorbs the back by oral administration and present the concentration height in blood.Utilize the male mouse of Wister kind (10-15 week) to test some exemplary compounds, test-results is listed among the table 3.
Test compound in the table 3 number is equivalent to the derivative number in the table 1.According to ordinary method, measured concentration level in blood plasma as test organisms with biological assay with micrococcus luteus (Micrococcus Luteus IFO 12708).
Table 3
The concentration (mcg/ml) of compound number dosage in blood plasma
(mg/kg) 1 hour 3 hours 5 hours
13 20 8.0 26.4 20.0
18 20 10.4 23.0 14.6
19 20 4.2 21.5 25.8
22 20 7.3 18.3 11.5
23 20 6.3 12.0 5.5
24 20 3.9 11.5 5.9
28 20 4.7 12.2 10.6
43 20 13.5 22.0 12.5
Benzoxazine
Rifomycin 100 0.05＞0.05＞0.05＞
(known compound)
Contain the antiseptic-germicide of Ryfamycin derivative of the present invention, can adopt any dose of shape to come per os, enteron aisle, partial or parenteral dispensing as effective constituent.These agent shapes are as tablet, capsule, pill, syrup, suppository, ointment etc.Used carrier normally is suitable for the nonactive pharmaceutical carrier (solid of organic or inorganic or liquid vehicle) of per os, enteron aisle or other non-enteron aisle dispensing in antiseptic-germicide agent shape of the present invention.This class carrier is as oil of crystalline cellulose, gelatin, lactose, starch, Magnesium Stearate, talcum, plant or animal or fat, natural gum or polyalkylene glycol.In this dose of shape, the ratio of antiseptic-germicide of the present invention and carrier is in 0.2-100(weight) do not wait between the %.Antiseptic-germicide of the present invention can contain another kind of pharmaceutical cpd, for example can with the another kind of antiseptic-germicide of antiseptic-germicide compatibility of the present invention.In this case, antiseptic-germicide of the present invention not necessarily must be the principal constituent in this agent shape.
The dispensing dosage of antiseptic-germicide of the present invention should be able to reach required effect and not have any pair of effect.Though actual dispensing dosage will be determined that the day dispensing dosage of antiseptic-germicide of the present invention is generally about 10 milligrams～about 10 grams for the adult by the doctor, be preferably about 20 milligrams～about 5 grams.Antiseptic-germicide of the present invention can preferably contain the pharmaceutical dosage unit form dispensing of 3 milligrams～1 gram activeconstituents to contain 1 milligram～5 grams.
The present invention is described more specifically and illustrate by the following example; But should know that the present invention is not limited by these embodiment, not exceed the scope of the invention and under the prerequisite of spirit of the present invention, can change, change and change.
In the following example, infrared absorption spectrum is pressed into little cake with sample again after with the Potassium Bromide grinding powder and measures; Nuclear magnetic resonance spectrum is using tetramethylsilane to do to measure under the conditions such as mark mark and full deuteriochloroform solution.
Embodiment 1
(3
1Synthesizing of-Jia base benzoxazine rifomycin)
100 milliliters of ethanolic solns of 5.0 gram 3-methyl-2-nitrophenolss are mixed with 0.5 gram, 10% palladium, one charcoal.At room temperature, in this solution, fed hydrogen 4 hours while stirring.From reaction mixture, leach palladium-charcoal by strainer, obtain 4.44 gram crude product 2-amino-3-methylphenols behind the pressure reducing and steaming solvent.
In 200 milliliters of toluene dissolving 16.7 gram rifamycin-Ss and 4.44 restrain crude product 2-amino-3-methylphenol, under room temperature, stirred one day.In reaction mixture, add 500 milliliters of toluene, in succession with sodium bicarbonate aqueous solution, water and salt solution washing, anhydrous sodium sulfate drying.After leaching siccative, with 300 milliliters of ethanol displacement toluene.Add 16.7 gram Manganse Dioxide, this mixture at room temperature reacted one day.Leach Manganse Dioxide by means of strainer, remove solvent under reduced pressure.Use Wakogel
C-200 carries out silica gel column chromatography purifying resistates, and elutriant is chloroform-acetone (95: 5), obtains 9.99 grams required 3
1-Jia base benzoxazine rifomycin.
Thin-layer chromatography
Rf value (Rf)=0.28, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1).
Embodiment 2
(synthesizing of No. 1 derivative)
Dissolving 1.0 grams are pressed embodiment 1 operating performance synthetic 3 in 10 milliliters of dimethyl alums
1-Jia base benzoxazine rifomycin adds 0.2 gram dimethylamine hydrochloride, 0.35 milliliter of triethylamine and 1.0 gram Manganse Dioxide in this solution, reaction three days stirs the mixture under the room temperature.Add ethyl acetate and dilute this reaction mixture, the filtering insoluble substance.Water, dilute hydrochloric acid, water and salt solution wash filtrate in succession remove ethyl acetate under reduced pressure then.Use Wakogel
C-200 carries out silica gel column chromatography purifying resistates twice, and elutriant is an ethyl acetate, then the resistates that obtains is dissolved in ethyl acetate-normal hexane, and crystallization goes out No. 1 required derivative of 0.09 gram.
Embodiment 3
(synthesizing of No. 2 derivative)
Embodiment 1 operation synthetic 1.0 grams 3 are pressed in dissolving in 10 milliliters of dimethyl alums
1-Jia base benzoxazine rifomycin adds 0.27 milliliter of N-methyl-isobutyl amine and 1.0 gram Manganse Dioxide in this solution, stirred this mixture 8 hours under room temperature.Handle according to embodiment 2 identical modes and to obtain No. 2 required derivative of 0.12 gram behind this reaction mixture.
Embodiment 4
(synthesizing of No. 3 derivative)
Except replacing N-methyl isobutylamine, reaction times to change 9 into beyond the highest heavens by 8 hours with two (2-ethoxyethyl) amine of 0.4 gram, repeat the operation steps of embodiment 3, obtain No. 3 required derivative of 0.15 gram.
Embodiment 5
(synthesizing of No. 4 derivative)
Except replacing N-methyl isobutylamine with 0.21 milliliter of tetramethyleneimine and the reaction times being changed into 5 hours by 8 hours, repeat the operation of embodiment 3, obtain No. 4 required derivative of 0.20 gram.
Embodiment 6
(synthesizing of No. 5 derivative)
Except replacing N-methyl isobutylamine with 0.25 milliliter of piperidines and the reaction times being changed into 5 hours by 8 hours, repeat the operation steps of embodiment 3, obtain No. 5 required derivative of 0.54 gram.
Embodiment 7
(synthesizing of No. 6 derivative)
Will (according to Helv.Chim.Acta, 56,2348, the method preparation of introducing in (1973)) 1.0 grams 4
110 milliliters of dimethyl alum solution of-Jia base benzoxazine rifomycin and 0.2 gram dimethylamine hydrochloride, 0.34 milliliter of triethylamine and 1.0 restrain Manganse Dioxide and mix, under room temperature, stir this mixture to react 8 hours, handle this reaction mixture according to embodiment 2 identical methods then, obtain No. 6 required derivative of 0.61 gram.
Embodiment 8
(synthesizing of No. 7 derivative)
Except replacing dimethylamine hydrochloride and triethylamine with 0.22 milliliter of thyl methyl amine and the reaction times being changed into 5 hours by 8 hours, repeat the operation steps of embodiment 7, obtain required No. 7 derivative of 0.53 gram.
Embodiment 9
(synthesizing of No. 8 derivative)
Except replacing dimethylamine hydrochloride and triethylamine with 0.26 milliliter of diethylamine and the reaction times being changed into one day by 8 hours, repeat the operation steps of embodiment 7, draw No. 8 derivative of 0.38 gram.
Embodiment 10
(synthesizing of No. 9 derivative)
Except replacing dimethylamine hydrochloride and triethylamine with 0.30 milliliter of N-methyl isobutylamine and the reaction times being changed into 3 hours by 8 hours, repeat the operation steps of embodiment 7, draw No. 9 derivative of 0.48 gram that desire is wanted.
Embodiment 11
(synthesizing of No. 10 derivative)
Remove with two (2-ethoxyethyl) amine of 0.40 gram and replace dimethylamine hydrochlorides and triethylamine and changed the reaction times into 2 beyond the highest heavens by 8 hours, repeat the operation steps of embodiment 7, draw required 0.30 and restrain No. 10 derivative.
Embodiment 12
(synthesizing of o.11 derivative)
Except replacing dimethylamine hydrochloride and triethylamine with 0.18 milliliter of propylene imines and the reaction times being changed into 2 days by 8 hours, repeat the operation steps of embodiment 7, draw the required o.11 derivative of 0.15 gram.
Embodiment 13
(synthesizing of No. 12 derivative)
Except replacing dimethylamine hydrochloride and triethylamine with 0.17 milliliter of azetidine and the reaction times being changed into 2 hours by 8 hours, repeat the operation steps of embodiment 7, draw No. 12 required derivative of 0.43 gram.
Infrared absorption spectrum ν (cm
-1):
3450，2970，2940，2890，1719，1648，1610，1475，
1399，1375，1302，1258，1220，1167，1140，1068，
1042，980，918，809，772，680，591 and 418
1H-nuclear magnetic resonance spectrum δ (ppm):
0.48，0.78，0.94（CHCH
3），1.80，1.91，2.00，2.21，
2.38，3.05（CH
3），4.36（CH
2NCH
2），6.13，7.56
(proton of aromatic ring) and 15.17(phenol proton).
Ultimate analysis (C
47H
55N
3O
12) result:
Calculated value (%): C66.10; H6.49; N4.92
Measured value (%): C65.95; H6.36; N5.10.
Embodiment 14
(synthesizing of No. 13 derivative)
Except replacing dimethylamine hydrochloride and triethylamine with 0.20 milliliter of tetramethyleneimine and the reaction times being changed into 1 hour by 8 hours, repeat the operation steps of embodiment 7, obtain No. 13 derivative of 0.61 gram.
Infrared absorption spectrum ν (cm
-1):
3550，2960，2920，2870，1712，1650，1599，1460，
1388，1360，1342，1320，1284，1251，1206，1160，
1130，1180，1160，1140，974，943，916，842，810，
764，684，660，582 and 576
Proton NMR spectrum δ (ppm):
0.50，0.77，0.93（CHCH
3），1.80，2.00，2.10，2.19，
2.54，3.04（CH
3），3.63（CH
2NCH
2），6.50，7.60
(aromatic ring proton) and 15.20(phenol proton)
Ultimate analysis (C
48H
57N
3O
12) result
Calculated value (%): C66.42; H6.62; N4.84
Measured value (%): C66.55; H6.58; N4.72
Embodiment 15
(synthesizing of No. 14 derivative)
Except with 0.24 milliliter
Pyridine replaces dimethylamine hydrochloride and triethylamine and the reaction times was changed into outside 4 hours by 8 hours, repeats the operation steps of embodiment 7, draws No. 14 required derivative of 0.50 gram.
Infrared absorption spectrum ν (cm
-1):
3460，2945，2830，1720，1660，1602，1584，1502，
1460，1421，1380，1360，1320，1305，1246，1200，
1180，1136，1105，1086，1056，1043，996，962，
940，908，878，830，803，784，742，704，676，644
and 600
Proton NMR spectrum δ (ppm):
1.47,1.80,1.98(CHCH
3), 1.72(
Pyridine ring proton),
1.80，2.03，2.13，2.20，2.40，3.03（CH
3），
6.51,7,77(aromatic ring proton) and 14.67(phenol proton)
Ultimate analysis (C
49H
59N
3O
12)
Calculated value (%): C66.73; H6.74; N4.76
Measured value (%): C66.83; H6.67; N4.64
Embodiment 16
(synthesizing of No. 15 derivative)
Except replacing dimethylamine hydrochloride and triethylamine with 0.28 milliliter of hexamethylene imine and the reaction times being changed into 5 hours by 8 hours, repeat the operation steps of embodiment 7, draw No. 15 required derivative of 0.73 gram.
Embodiment 17
(synthesizing of No. 16 derivative)
With 1.0 grams 6
1-Jia base benzoxazine rifomycin is (according at Helv.Chim. Acta.56, the method preparation of record 2348(1973)) 10 milliliters of dimethyl alum solution mix with 0.17 milliliter of azetidine and 1.0 gram Manganse Dioxide, and this mixture of stirring is 31 hours under the room temperature.Handle this reaction mixture according to the identical mode of implementing 2 then, draw No. 16 required derivative of 0.41 gram.
Embodiment 18
(synthesizing of No. 17 derivative)
Except replacing azetidine with 0.21 milliliter of tetramethyleneimine and the reaction times being changed into 4 hours by 31 hours, repeat the operation steps of embodiment 17, draw No. 17 required derivative of 0.54 gram.
Infrared absorption spectrum ν (cm
-1):
3460，2980，2940，2880，1720，1646，1600，1470，
1420，1398，1360，1322，1262，1164，1140，1098，
1070，980，952，920，817，772，698，646，570，540
and 438
Proton NMR spectrum δ (ppm)
-0.16，0.33，0.80，0.97（CHCH
3），1.81，1.99，2.07，
2.23，2.37，3.00（CH
3），3.57（CH
2NCH
2），6.77，7.61
(aromatic ring proton) and 15.07(phenol proton).
Ultimate analysis (C
48H
57N
3O
12) result:
Calculated value (%): C66.42; H6.62; N4.84
Measured value (%): C66.62; H6.43; N4.97
Embodiment 19
(4
1Synthesizing of-ethyl benzoxazine rifomycin)
Add 7.66 gram SODIUMNITRATE and 10.0 gram 4-ethylphenols in the mixture of forming by 130 milliliters of ether and 130 ml waters under stirring, add 13 milliliters of concentrated hydrochloric acids therein, this reaction was carried out 3 days.In reaction mixture, add 300 ml waters, and with 500 milliliters of extracted with diethyl ether, anhydrous sodium sulfate drying is used in extraction liquid priority water and saturated common salt water washing then.After leaching siccative, the pressure reducing and steaming solvent obtains 13.0 gram 4-ethyl-2-nitrophenolss.
In 260 milliliters of ethanolic solns of 13.0 gram 4-ethyl-2-nitrophenolss, add 1.3 grams, 10% palladium, one charcoal, in solution, feeding hydrogen 4 hours while stirring under the room temperature.Leach palladium-charcoal, the pressure reducing and steaming solvent obtains 10.68 gram crude product 2-amino-4-ethylphenols.
Dissolving 20.0 gram rifamycin-Ss and 4.73 gram gained crude product 2-amino-4-ethylphenols stirred one day in 400 milliliters of toluene.Handle this reaction mixture and carry out purifying according to the mode identical with embodiment 1, obtain 14.2 grams required 4
1-ethyl benzoxazine rifomycin.
Thin-layer chromatography
Rf=0.28, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 20
(synthesizing of No. 18 derivative)
Will be by 1.0 grams 4 of the operation steps synthetic among the embodiment 19
1-ethyl benzoxazine rifomycin is dissolved in the inferior rock of 10 milliliters of dimethyl, adds 0.17 milliliter of azetidine and 1.0 gram Manganse Dioxide therein, stirs this reaction mixture 7 hours under the room temperature.According to embodiment 2 in identical mode handle this reaction mixture, obtain No. 18 required derivative of 0.27 gram.
Infrared absorption spectrum ν (cm
-1):
3460，2970，2940，2880，1718，1658，1605，1505，
1470，1398，1375，1290，1260，1217，1166，1068，
980，940，920，815，770，680，550 and 418
Proton NMR spectrum δ (ppm):
0.54，0.77，0.95（CHCH
3），1.28，2.70（CH
2CH
3），
1.80，2.02，2.10，2.21，3.06（CH
3），4.34（CH
2NCH
2），
6.21，7.63（protons of aromatic ring）and 15.17（phenolic proton）
Ultimate analysis (C
43H
57N
3O
12)
Calculated value (%): C66.42; H:6.62; N4.84
Measured value (%): C66.24; H:6.71; N5.03
Embodiment 21
(synthesizing of No. 19 derivative)
Except replacing azetidine with 0.21 milliliter of tetramethyleneimine and the reaction times being changed into 3 hours by 7 hours, repeat the operation steps of embodiment 20, obtained No. 19 required derivative of 0.48 gram.
Infrared absorption spectrum ν (cm
-1):
3450，2970，2930，2870，1718，1644，1602，1505，
1460，1363，1350，1290，1256，1218，1162，1135，
1062，978，943，915，815，768，663，590，545 and
410
Proton NMR spectrum δ (ppm):
0.55，0.75，0.93（CHCH
3），1.29，2.90（CH
2CH
3），
1.82，1.98，2.00，2.17，3.07（CH
3），3.60（CH
2NCH
2），
6.60，7.68（protons of aromatic ring）and 15.15（phenolic proton）
Ultimate analysis (C
49H
59N
3O
12):
Calculated value (%): C66.73; H6.74; N:4.76
Measured value (%): C66.49; H6.97; N:4.86
Embodiment 22
(synthesizing of No. 20 derivative)
Except with 0.24 milliliter
Pyridine replaces azetidine and the reaction times was changed into outside 5 hours by 7 hours, repeats the operation steps among the embodiment 20, obtains No. 20 required derivative of 30.36 grams.
Embodiment 23
(6
1Synthesizing of-ethyl benzoxazine rifomycin)
6.7 milliliter of 61% nitric acid of dropping in the mixture of being made up of 130 milliliters of ether, 130 ml waters and 10.0 gram 2-ethylphenols that stirs down, this reaction mixture of stirring is 4 hours under the room temperature.With 300 milliliters of ethyl acetate extraction reaction mixtures,, use anhydrous sodium sulfate drying then with the salt solution washing.Leach pressure reducing and steaming solvent behind the siccative, resistates is through the silica gel column chromatography purifying, and elutriant is a chloroform, draws 5.75 gram 6-ethyl-2-nitrophenolss.
In 200 milliliters of ethanolic solns of 4.96 gram 6-ethyl-2-nitrophenolss, add 0.5 gram 10% palladium-charcoal, in solution, fed hydrogen 4.5 hours while stirring under the room temperature.Leach the palladium charcoal from mixture, solvent removed by evaporation at reduced pressure obtains 4.86 gram crude product 2-amino-6-ethylphenols then.
Dissolving 15.0 gram rifamycin-Ss and 3.25 gram gained crude product 2-amino-6-ethylphenols stirred this solution 1 day under the room temperature in 300 milliliters of toluene.Handle and the purified reaction mixture according to the mode identical then with embodiment 1, obtain 3.15 grams required 6
1-ethyl benzoxazine rifomycin.
Thin-layer chromatography:
Rf=0.27, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 24
(synthesizing of No. 21 derivative)
1.0 grams are pressed the operation steps synthetic 6 of embodiment 23
1-ethyl benzoxazine rifomycin is dissolved in 10 milliliters of dimethyl alums, adds 0.15 milliliter of azetidine and 1.0 gram Manganse Dioxide therein, stirs this reaction mixture one day under the room temperature.Handle this reaction mixture according to the mode identical then, obtain No. 21 required derivative of 0.36 gram) with embodiment 2.
Infrared absorption spectrum ν (cm
-1):
3460，2975，2940，2880，1725，1648，1608，1474，
1399，1378，1318，1265，1174，1140，1073，1050，
982，950，818，770，702 and 440
Proton NMR spectrum δ (ppm):
-0.20，0.39，0.83，1.01（CHCH
3），1.84，2.00，2.05，
2.28，3.03（CH
3），1.16，2.75（CH
2CH
3），4.36，
（CH
2NCH
2），6.46，7.72（protons of aromatic ring）
and 15.15（phenolic proton）
Ultimate analysis (C
48H
57N
3O
12)
Calculated value (%): C66.42; H6.62; N4.84
Measured value (%): C66.22; H6.80; N4.75
Embodiment 25
(synthesizing of No. 22 derivative)
Except replacing azetidine with 0.21 milliliter of tetramethyleneimine and the reaction times being changed into 2 days by 1 day, repeat the operation steps of embodiment 24, obtained No. 22 required derivative of 0.40 gram.
Infrared absorption spectrum ν (cm
-1):
3450，2970，2940，2875，1718，1640，1596，1465，
1410，1358，1342，1314，1258，1158，1132，1100，
1062，1040，975，946，810，770，684，598 and 430
Proton NMR spectrum δ (ppm):
-0.17，0.42，0.82，0.99（CHCH
3），1.84，1.98，2.04，
2.25，3.02（CH
3），1.19，2.94（CH
2CH
3），3.61（CH
2NCH
2），6.87，7.71（protons of aromatic ring）and 15.04（phenolic proton）
Ultimate analysis (C
49H
59N
3O
12):
Calculated value (%): C66.73; H6.74; N4.76
Measured value (%): C66.96; H6.54; N4.83
Embodiment 26
(4
1Synthesizing of-n-propyl benzo oxazine rifomycin)
Under ice-cooled, 11.0 milliliter of 61% nitric acid is added drop-wise to 10.0 gram 4-n-propyl phenol in the suspension of 50 ml waters, makes mixture temperature bring up to room temperature, and reaction was carried out 2 hours.With 300 milliliters of these reaction mixtures of ethyl acetate extraction, salt solution washing, anhydrous sodium sulfate drying.Leach siccative, steam solvent under the decompression.Resistates is purified with silica gel column chromatography, and the chloroform give elutriant draws 8.69 gram 4-n-propyl-2-nitrophenolss.
In 350 milliliters of ethanolic solns of 8.69 gram 4-n-propyl-2-nitrophenolss, add 0.8 gram, 10% palladium, one charcoal, under room temperature while stirring to wherein feeding hydrogen 3.5 hours.Decompression steams solvent after leaching palladium-charcoal, draws 7.78 gram crude product 2-amino-4-n-propyl phenol.
Dissolving 20.0 gram rifamycin-Ss and 4.35 gram gained crude product 2-amino-4-n-propyl phenol stirred one day under room temperature in 400 milliliters of toluene.Then according to handling and this reaction mixture of purifying with embodiment 1 same way as, obtain 10.86 grams required 4
1-n-propyl benzo oxazine rifomycin.
Thin-layer chromatography:
Rf=0.36, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 27
(synthesizing of No. 23 derivative)
Operation steps synthetic 1.0 grams 4 according to embodiment 26
1-n-propyl benzo oxazine rifomycin is dissolved in 10 milliliters of dimethyl alums, adds 0.16 milliliter of azetidine and 1.0 gram Manganse Dioxide in this solution, stirs this reaction mixture 4 hours under room temperature.According to the mode reaction mixture identical, draw No. 23 required derivative of 0.29 gram then with embodiment 2.
Infrared absorption spectrum ν (cm
-1):
3450，2955，2925，2865，1717，1645，1600，1500，
1462，1384，1364，1290，1250，1206，1159，1132，
1084，1065，976，943，915，818，772，684 and 595
Proton NMR spectrum δ (ppm):
0.55，0.79，0.95（CHCH
3），1.03（CH
2CH
2CH
3），1.81，
1.90，2.02，2.21，3.07（CH
3），4.33（CH
2NCH
2），
6.18，7.61（protons of aromatic ring）and 15.16（phenolic proton）
Ultimate analysis (C
49H
59N
3O
12):
Calculated value (%): C66.73; H6.74; N4.76
Measured value (%): C66.57; H6.88; N4.91
Embodiment 28
(synthesizing of No. 24 derivative)
Except replacing azetidine with 0.20 milliliter of tetramethyleneimine and the reaction times being changed into 2.5 hours by 4 hours, repeat the operation steps of embodiment 27, obtain No. 24 required derivative of 0.51 gram.
Infrared absorption spectrum ν (cm
-1):
3450，2955，2925，2875，1715，1645，1596，1498，
1458，1395，1357，1340，1282，1250，1200，1152，
1124，1075，1060，1032，972，948，908，814，766，
660，592 and 500
Proton NMR spectrum δ (ppm):
0.55，0.78，0.95（CHCH
3），1.01（CH
2CH
2CH
3），1.81，
1.91，2.02，2.19，3.07（CH
3），3.58（CH
2NCH
2），
6.62，7.71（protons of aromatic ring）and 15.16（phenolic proton）
Ultimate analysis (C
50H
61N
3O
13):
Calculated value (%): C67.02; H6.86; N4.69
Measured value (%): C67.29; H6.98; N4.42
Embodiment 29
(6
1Synthesizing of-n-propyl benzo oxazine rifomycin)
The nitric acid of 11.0 milliliter 61% of dropping in the mixture of being made up of 100 milliliters of ether of 100 ml waters and 10.0 gram 2-n-propyl phenol that stirs down, this reaction mixture of stirring is 12 days under room temperature.Reaction mixture is used anhydrous sodium sulfate drying with 200 milliliters of ethyl acetate extractions.After leaching siccative, the pressure reducing and steaming solvent.Resistates obtains 3.76 gram 6-n-propyl-2-nitrophenolss after silica gel column chromatography is purified (1: 1 mixture of chloroform-normal hexane is made elutriant).
In the suspension of 20 ml waters, add 21.6 gram sodium bisulfites to 3.76 gram 6-n-propyl-2-nitrophenolss, stirred one hour down in 60 ℃.Add sodium bicarbonate and neutralize behind this reaction mixture, with 200 milliliters of ethyl acetate extractions, anhydrous sodium sulfate drying.Leach siccative, decompression steams solvent, obtains 2.93 gram crude product 2-amino-6-n-propyl phenol.
2.93 gram crude product 2-amino-6-n-propyl phenol of dissolving 13.5 gram rifamycin-Ss and gained stirred the mixture under the room temperature one day in 270 milliliters of toluene.Then according to the mode identical this reaction mixture of handling and purify with embodiment 1, obtain 8.21 grams required 6
1-n-propyl benzo oxazine rifomycin.
Thin-layer chromatography:
Rf=0.23, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 30
(synthesizing of No. 25 derivative)
Operating performance synthetic 2.0 grams 6 according to embodiment 29
1-n-propyl benzo oxazine rifomycin is dissolved in 20 milliliters of dimethyl alums, to wherein adding 0.33 milliliter of azetidine and 2.0 gram Manganse Dioxide, stirs this mixture 8.5 hours under the room temperature.According to handling this reaction mixture, obtain No. 25 required derivative of 0.58 gram then as mode same among the embodiment 2.
Embodiment 31
(synthesizing of No. 26 derivative)
Except replacing azetidine with 0.4 milliliter of tetramethyleneimine and the reaction times being changed into 4 hours by 8.5 hours, repeat the operation steps of embodiment 30, obtained No. 26 derivative of 0.75 gram.
Embodiment 32
(4
1Synthesizing of-sec.-propyl benzo oxazine rifomycin)
In the suspension of 14 ml waters, drip 4.0 milliliter of 70% nitric acid to 5.0 gram 4-hydroxyl isopropyl benzenes under ice-cooled, make mixture temperature bring up to room temperature and make to react and continue 40 minutes.After adding 500 ml waters therein, reaction mixture is with 500 milliliters of ethyl acetate extractions, water and saturated common salt water washing in succession, anhydrous sodium sulfate drying.After leaching siccative, solvent removed by evaporation at reduced pressure.Resistates draws 5.07 gram 4-sec.-propyl-2-nitrophenolss after silica gel column chromatography (ethyl acetate is made elutriant) is purified.
Palladium-the charcoal that in 150 milliliters of ethanolic solns of 5.07 gram 4-sec.-propyl-2-nitrophenolss, adds 0.5 gram 10%, under the room temperature while stirring to wherein feeding hydrogen 4 hours.Leach palladium-charcoal, obtain 4.87 gram crude product 2-amino-4-isopropyl-phenols after the solvent removed by evaporation at reduced pressure.
10.0 gram rifamycin-Ss and 8.26 gram crude product 2-amino-4-isopropyl-phenols are dissolved in 200 milliliters of toluene, stirred this reaction mixture one day under the room temperature.Then according to handling and this reaction mixture of purifying as embodiment 1 identical mode, draw 4.24 grams required 4
1-sec.-propyl benzo oxazine rifomycin.
Thin-layer chromatography
Rf=0.29, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 33
(synthesizing of No. 27 derivative)
With 1.0 grams by the operation steps synthetic 4 of embodiment 32 '-sec.-propyl benzo oxazine rifomycin is dissolved in 10 milliliters of dimethyl alums, adds 1.0 gram Manganse Dioxide and 0.17 milliliter of azetidine therein, stirs this mixture 19 hours under room temperature.By handling this reaction mixture, obtain No. 27 required derivative of 0.21 gram then as embodiment 2 identical modes.
Embodiment 34
(synthesizing of No. 28 derivative)
Except replacing azetidine with 0.20 milliliter of tetramethyleneimine and the reaction times being changed into 3 days by 19 hours, repeat the operation steps of embodiment 33, draw No. 28 required derivative of 0.39 gram.
Infrared absorption spectrum ν (cm
-1):
3450，2970，2940，2870，1720，1654，1598，1500，
1464，1405，1372，1290，1260，1218，1170，1148，
1092，1070，980，950，918，815，769，660，596，
558 and 420
Proton NMR spectrum δ (ppm):
0.59，0.76，0.92（CHCH
3），1.35（CH
3CHCH
3），1.82，
2.00，2.10，3.05（CH
3），3.53（CH
2NCH
2），6.64，
7.77（protons of aromatic ring）and 15.05（phenolic proton）
Ultimate analysis (C
50H
61N
3O
12):
Calculated value (%): C67.02; H6.86; N4.69
Measured value (%): C67.23; H6.98; N4.49
Embodiment 35
(synthesizing of No. 29 derivative)
Except with 0.24 milliliter
Pyridine replaces azetidine and the reaction times was changed into outside 1 day by 19 hours, repeats the operation steps of embodiment 33, draws No. 29 required derivative of 0.45 gram.
Embodiment 36
(6 '-sec.-propyl benzo oxazine rifomycin synthetic)
The nitric acid of 22.0 milliliter 61% of dropping at room temperature stirred this mixture two days then in the mixture of being made up of 200 ml waters, 200 milliliters of hexyl ethers and 20.0 gram isopropyl-phenols that stirs down.Reaction mixture is with 200 milliliters of ethyl acetate extractions, anhydrous sodium sulfate drying.Leach siccative then, steaming under reduced pressure desolventizes.Resistates is purified with silica gel column chromatography, and chloroform-normal hexane (1: 1) is made elutriant, draws 7.69 gram 6-sec.-propyl-2-nitrophenolss.
In 200 milliliters of ethanolic solns of 7.69 gram 6-sec.-propyl-2-nitrophenolss, add 0.77 gram 10% palladium-charcoal, under room temperature while stirring to wherein feeding hydrogen 4 hours.Leach palladium-charcoal, remove under reduced pressure and obtain 6.39 gram crude product 2-amino-6-isopropyl-phenols after desolvating.
The crude product 2-amino-6-isopropyl-phenol of 26.9 gram rifamycin-Ss and 6.39 gram gained is dissolved in 500 milliliters of toluene, at room temperature stirred this mixture one day.Then by this reaction mixture of handling and purify as embodiment 1 identical mode, obtain 5.30 grams required 6 '-sec.-propyl benzo oxazine rifomycin.
Thin-layer chromatography
Rf=0.28, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 37
(synthesizing of No. 30 derivative)
1.0 grams 6 '-add 0.16 milliliter of azetidine and 1.0 gram Manganse Dioxide after sec.-propyl benzo oxazine rifomycin is dissolved in 10 milliliters of dimethyl alums again, room temperature and stir under make this mixture reaction two days.According to handling this reaction mixture, obtain No. 30 required derivative of 0.07 gram then as embodiment 2 identical modes.
Embodiment 38
(4 '-normal-butyl benzo oxazine rifomycin synthetic)
The ice-cooled nitric acid that drips 3.7 milliliter 70% down to 5.0 gram 4-normal-butyl phenol in the suspension of 14 ml waters makes mixture temperature bring up to room temperature then, and reaction was carried out 40 minutes.After wherein adding 500 ml waters, reaction mixture is with 500 milliliters of ethyl acetate extractions, and anhydrous sodium sulfate drying is used in water and salt solution washing in succession.Leach siccative, decompression is steamed down and is desolventized, and resistates is purified with silica gel column chromatography, and ethyl acetate is made elutriant, obtains 6.20 gram 4-normal-butyl-2-nitrophenolss.
Add the palladium-charcoal of 0.6 gram 10% in 300 milliliters of ethanolic solns of 6.20 gram 4-normal-butyl-2-nitrophenolss, the following stirring of room temperature is following to feed hydrogen 4 hours.After leaching palladium-charcoal, solvent removed by evaporation at reduced pressure obtains 5.14 gram crude product 2-amino-4-normal-butyl phenol.
The crude product 2-amino-4-normal-butyl phenol of dissolving 18.0 gram rifamycin-Ss and 5.14 gram gained stirred this mixture one day under the room temperature in 360 milliliters of toluene.Then by handling and the purified reaction mixture as embodiment 1 identical mode, obtain 7.61 grams required 4 '-normal-butyl benzo oxazine rifomycin.
Thin-layer chromatography:
Rf=0.27, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 39
(synthesizing of No. 31 derivative)
Dissolving 1.0 grams 4 in 10 milliliters of dimethyl alums '-normal-butyl benzo oxazine rifomycin (pressing the operation steps synthetic of embodiment 38), add 0.17 milliliter of azetidine and 1.0 gram Manganse Dioxide therein, stirred this mixture 2 hours under the room temperature.Then, by handling this reaction mixture, draw No. 31 required derivative of 0.09 gram as embodiment 2 identical modes.
Embodiment 40
(synthesizing of No. 32 derivative)
Except replace repeating the azetidine operation steps of embodiment 39 with 0.20 milliliter of tetramethyleneimine, draw No. 32 required derivative of 0.63 gram.
Infrared absorption spectrum ν (cm
-1):
3440，2970，2930，2870，1718，1662，1599，1501，
1460，1367，1348，1290，1258，1220，1162，1134，
1085，1064，1040，976，950，915，814，770 and 592
Proton NMR spectrum δ (ppm):
0.57，0.77，0.93（CHCH
3），0.97（（CH
2）
3CH
3），1.81，
2.00，2.10，2.16，3.06（CH
3），3.57（CH
2NCH
2），
6.59，7.66（protons of aromatic ring）and 5.14（phenolic proton）
Ultimate analysis (C
51H
63N
3O
12):
Calculated value (%): C67.31; H6.98; N4.62
Measured value (%): C67.44; H7.17; N4.41
Embodiment 41
(4 '-sec-butyl benzo oxazine rifomycin synthetic)
In by 50 milliliters of ether, drip 7.5 milliliter 61% nitric acid in the mixture that 50 ml waters and 10.0 gram 4-sec-butyl phenols are formed under ice-cooled, make mixture temperature bring up to room temperature then, and make reaction continuation 4 days.Reaction mixture washs with 300 milliliters of ethyl acetate extractions, salt solution, anhydrous sodium sulfate drying.Remove solvent under reduced pressure after leaching siccative.Resistates is through the silica gel column chromatography purifying, and the chloroform give elutriant draws 14.71 gram 4-sec-butyl-2-nitrophenolss.
In 300 milliliters of ethanolic solns of 14.71 gram 4-sec-butyl-2-nitrophenolss, add 1.4 gram 10% palladium-charcoals, fed hydrogen under the room temperature while stirring 5 hours.Remove solvent under reduced pressure after leaching palladium-charcoal, draw 10.1 gram crude product 2-amino-4-sec-butyl phenols.
The crude product 2-amino-4-sec-butyl phenol of 20.0 gram rifamycin-Ss and 5.22 gram gained is dissolved in 400 milliliters of toluene, stirs this mixture diel under the room temperature.Then by handle this reaction mixture purifying in addition then as embodiment 1 identical mode, draw 6.51 grams required 4 '-sec-butyl benzo oxazine rifomycin.
Thin-layer chromatography:
Rf=0.34, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 42
(synthesizing of No. 33 derivative)
By operation steps synthetic 1.0 gram 4 of embodiment 41 '-sec-butyl benzo oxazine rifomycin is dissolved in 10 milliliters of dimethyl alums, adds 0.16 milliliter of azetidine and 1.0 gram Manganse Dioxide therein, stirred the mixture under the room temperature 6.5 hours.By same way as reaction mixture, obtain No. 33 required derivative of 0.14 gram then as embodiment 2.
Embodiment 43
(synthesizing of No. 34 derivative)
Except replacing azetidine with 0.20 milliliter of tetramethyleneimine and the reaction times being changed into one day by 6.5 hours, repeat the operation steps of embodiment 42, draw No. 34 required derivative of 0.17 gram.
Infrared absorption spectrum ν (cm
-1):
3450，2970，2940，2880，1720，1668，1600，1505，
1458，1407，1368，1345，1290，1258，1214，1166，
1142，1090，1068，1043，980，946，918，818，772，
665，640，598，580 and 560
Proton NMR spectrum δ (ppm):
0.57，0.77，0.94（CHCH
3），0.94，1.38（CH
3CHCH
2CH
3）
1.83，1.91，2.03，2.13，3.09（CH
3），3.55（CH
2NCH
2），
6.71，7.79（protons of aromatic ring）and 15.11（phenolic proton）
Ultimate analysis (C
51H
63N
3O
12):
Calculated value (%): C67.31; H6.98; N4.62
Measured value (%): C67.55; H7.17; N4.31
Embodiment 44
(4 '-cyclopentyl benzoxazine rifomycin synthetic)
In 50 ml waters, 50 milliliters of ether and 4-encircle the nitric acid that drips 2.1 milliliter 61% in the mixture that penta phenol forms, and add the S-WAT of catalytic amount again, at room temperature stir this mixture then 5 days.Reaction mixture is with 200 milliliters of ethyl acetate extractions, anhydrous sodium sulfate drying.Leach siccative, remove solvent under reduced pressure, resistates silica gel column chromatography purifying, chloroform-normal hexane (1: 1) is made elutriant, obtains 3.60 gram 4-cyclopentyl-2-nitrophenolss.
In the 3.60 gram 4-cyclopentyl-suspension of 2-nitrophenols in 20 ml waters, add 27.3 gram sodium bisulfites, stirred the mixture 1 hour under 60 ℃.After in this reaction mixture, adding 300 ml waters, filter the crystal of collecting precipitation, obtain 1.88 gram crude product 2-amino-4-cyclopentyl phenol.
The crude product 2-amino-4-cyclopentyl phenol of dissolving 7.38 gram rifamycin-Ss and 1.88 gram gained stirred this mixture one day under the room temperature in 140 milliliters of toluene.According to handling and the purified reaction mixture as embodiment 1 same way as, obtain 6.61 grams required 4 '-the refreshing mycin of cyclopentyl benzoxazine profit.
Thin-layer chromatography:
Rf=0.27, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 45
(synthesizing of No. 35 derivative)
In 20 milliliters of dimethyl alums dissolving 2.0 grams press the operation steps synthetic 4 of embodiment 44 '-cyclopentyl benzoxazine rifomycin, add 0.32 milliliter of azetidine and 2.0 gram Manganse Dioxide therein, stir the mixture under the room temperature and reacted 4 hours.According to handling this reaction mixture, obtain No. 35 required derivative of 0.26 gram then with embodiment 2 identical modes.
Embodiment 46
(synthesizing of No. 36 derivative)
Repeat the operation steps of embodiment 45 except replacing the azetidine, obtain No. 36 required derivative of 0.77 gram with 0.39 milliliter of tetramethyleneimine.
Embodiment 47
(4 '-cyclohexyl benzo oxazine rifomycin synthetic)
Ice-cooled down, in the mixture that 50 ml waters, 50 milliliters of ether and 10.0 gram 4-cyclohexylphenol are formed, drip 12.6 milliliter 60% nitric acid.Make mixture temperature bring up to room temperature and reacted one day.After adding 500 ml waters, reaction mixture is with 500 milliliters of ethyl acetate extractions, water and salt solution washing in succession, anhydrous sodium sulfate drying.Leach siccative, steaming desolventizes.Resistates is purified with silica gel column chromatography, uses the chloroform give elutriant, obtains 6.92 gram 4-cyclohexyl-2-nitrophenolss.
In 270 milliliters of ethanolic solns of 6.81 gram 4-cyclohexyl-2-nitrophenolss, add the palladium-charcoal of 0.7 gram 10%, fed hydrogen under the room temperature while stirring 4 hours.Leach palladium-charcoal, remove under reduced pressure and obtain 4.41 gram crude product 2-amino-4-cyclohexylphenol behind the solvent.
Dissolving 15.88 gram rifamycin-Ss and 4.41 gram gained crude product 2-amino-4-cyclohexylphenol stirred this mixture one day under the room temperature in 320 milliliters of toluene.Then by handling and this reaction mixture of purifying as embodiment 1 identical mode, obtain 7.77 grams required 4 '-cyclohexyl benzo oxazine rifomycin.
Thin-layer chromatography
Rf=0.28, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 48
(synthesizing of No. 37 derivative)
In 10 milliliters of dimethyl alums dissolving 1.0 grams press the operation steps synthetic 4 of embodiment 47 '-cyclohexyl benzo oxazine rifomycin, add 0.16 milliliter of azetidine and 1.0 again and restrain Manganse Dioxide.Stirred this mixture 7 hours under the room temperature.By handling this reaction mixture, obtain No. 37 required derivative of 0.09 gram then as embodiment 2 identical modes.
Embodiment 49
(synthesizing of No. 38 derivative)
Except replacing azetidine with 0.19 milliliter of tetramethyleneimine and the reaction times being changed into 4 hours by 7 hours, repeat the operation steps of embodiment 48, draw No. 38 required derivative of 0.36 gram.
Embodiment 50
(3 ', 4 '-dimethyl benzo oxazine rifomycin synthetic)
To 12.2 grams 3, add 7.48 milliliter 61% nitric acid in 100 milliliters of acetic acid solutions of 4-xylenol, make temperature of reaction remain on 20 ℃ simultaneously.Under room temperature, stir the mixture then.Add 200 milliliters of ethyl acetate in reaction mixture, water, sodium bicarbonate aqueous solution, water and salt solution wash this mixture in succession, remove ethyl acetate then under reduced pressure.Resistates is purified through silica gel column chromatography, and the chloroform give elutriant draws 0.69 gram 3,4-dimethyl-2-nitrophenols.
To 0.69 gram 3, add the palladium-charcoal of 0.1 gram 10% in 20 milliliters of ethanolic solns of 4-dimethyl-2-nitrophenols, fed hydrogen under the room temperature while stirring 3.5 hours.Leach palladium-charcoal, remove solvent under reduced pressure, obtain 0.56 gram crude product 3,4-dimethyl-2-amino-phenol.
The crude product 3 of dissolving 2.69 gram rifamycin-Ss and 0.53 gram gained in 70 milliliters of toluene, 4-dimethyl-2-amino-phenol stirred this mixture 5 days under the room temperature.Then by the mode identical this reaction mixture of handling and purify with embodiment 1, obtain 1.74 grams required 3 ', 4 '-dimethyl benzo oxazine rifomycin.
Thin-layer chromatography
Rf=0.29, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 51
(synthesizing of No. 39 derivative)
In 5 milliliters of dimethyl alums dissolving 0.8 gram press the operation steps synthetic 3 of embodiment 50 ', 4 '-add 0.17 milliliter of tetramethyleneimine and 0.8 again behind the dimethyl benzo oxazine rifomycin to restrain Manganse Dioxide, stirred the mixture under the room temperature 22 hours.According to the mode reaction mixture identical, obtain No. 39 required derivative of 0.26 gram then with embodiment 2.
Embodiment 52
(3 ', 6 '-dimethyl benzo oxazine rifomycin synthetic)
Ice-cooled and stir down restrain the nitric acid of Dropwise 5 .2 milliliter 70% in the mixture that the 2.5-xylenols form by 130 ml waters, 130 milliliters of ether and 10.0.Make mixture temperature bring up to room temperature and continue reaction one day.After adding 500 ml waters, reaction mixture is with 500 milliliters of ethyl acetate extractions, water and salt solution washing successively, anhydrous sodium sulfate drying.Leach siccative, steaming desolventizes, resistates silica gel column chromatography purifying, and the chloroform give elutriant obtains 3.83 grams 3,6-dimethyl-2-nitrophenols.
To 3.83 grams 3, add 0.4 gram 10% palladium-charcoal in 150 milliliters of ethanolic solns of 6-dimethyl-2-nitrophenols, fed hydrogen under the room temperature while stirring 4 hours.Leach palladium-charcoal, remove solvent under reduced pressure, obtain 2.2 gram crude product 2-amino-3, the 6-xylenol.
The crude product 2-amino-3 of dissolving 11.19 gram rifamycin-Ss and 2.2 gram gained in 200 milliliters of toluene, the 6-xylenol stirred the mixture under the room temperature one day.Handle and this reaction mixture of purifying according to the mode identical with embodiment 1, draw 5.52 grams required 3 ', 6 '-dimethyl benzo oxazine rifomycin.
Thin-layer chromatography
Rf=0.15, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 53
(synthesizing of No. 40 derivative)
In 10 milliliters of dimethyl alums dissolving 1.0 grams press the operation steps synthetic 3 of embodiment 52 ', 6 '-dimethyl benzo oxazine rifomycin, add 0.17 milliliter of azetidine and 1.0 therein and restrain Manganse Dioxide, stirred the mixture under the room temperature 2 hours.According to the mode reaction mixture identical, obtain No. 40 required derivative of 0.51 gram then with embodiment 2.
Embodiment 54
(synthesizing of No. 41 derivative)
Except replacing azetidine with 0.2 milliliter of tetramethyleneimine and the reaction times being changed into 4 hours by 2 hours, repeat the operation steps of embodiment 53, obtain No. 41 required derivative of 30.62 grams.
Embodiment 55
(synthesizing of No. 42 derivative)
Except with 0.24 milliliter
Pyridine replaces azetidine and the reaction times was changed into outside 7 hours by 2 hours, repeats the operation steps of embodiment 53, draws No. 42 required derivative of 0.86 gram.
Embodiment 56
(4 ', 6 '-dimethyl benzo oxazine rifomycin synthetic)
Make 200 milliliters of toluene solutions and 2.37 gram 6-amino-2 of 10 gram rifamycin-Ss, the mixing of 4-xylenol stirred the mixture under the room temperature 43 hours.Leach insoluble substance, filtrate successively with 5% sodium bicarbonate aqueous solution, water and salt solution washing, removes toluene under reduced pressure then.The resistates that obtains is dissolved in 200 ml methanol, adds 10 gram Manganse Dioxide therein, stirred the mixture under the room temperature 6.5 hours.Leach insoluble substance then, reduction vaporization filtrate is to doing.The resistates Wakogel that obtains
C-200 carries out the silica gel column chromatography purifying, and chloroform-acetone (95: 5) is made elutriant, draws the required derivative of 4.68 grams.
Thin-layer chromatography
Rf=0.25, purple red color spot (carrier: silica gel, solvent system: ethyl acetate).
Embodiment 57
(synthesizing of No. 43 derivative)
In 10 milliliters of dimethyl alums dissolving 1.0 grams press the operation steps synthetic 4 of embodiment 56 ', 6 '-dimethyl benzo oxazine rifomycin, add 0.12 milliliter of azetidine and 1.0 therein and restrain Manganse Dioxide, stirred the mixture under the room temperature one day.Then by as the identical mode reaction mixture of embodiment 2, obtain 0.14 and restrain No. 43 required derivative.
Infrared absorption spectrum ν (cm
-1):
3440，2970，2925，2875，1718，1640，1597，1464，
1384，1357，1306，1280，1257，1207，1160，1140，
1100，1068，1036，972，945，914，818，760 and 692
Proton NMR spectrum δ (ppm):
-0.17，0.33，0.81，0.98（CHCH
3），1.83，1.90，
1.98，2.10，2.28，2.41，3.01（CH
3），4.60
（CH
2NCH
2），7.45（proton of aromatic ring）and
15.26（phenolic proton）
Ultimate analysis (C
48H
57N
3O
12):
Calculated value (%): C66.42; H6.62; N4.84
Measured value (%): C66.20; H6.51; N5.03
Embodiment 58
(synthesizing of No. 44 derivative)
Except replacing azetidine with 0.20 milliliter of tetramethyleneimine and the reaction times being changed into 3.5 hours by one day, repeat the operation steps of embodiment 57, obtain No. 44 required derivative of 0.17 gram.
Embodiment 59
(3 '-methyl-6 '-sec.-propyl benzo oxazine rifomycin synthetic)
In 100 milliliters of acetic acid solutions of 10.16 gram thymols, add 50 milliliters of acetic acid solutions that are dissolved with 5.06 milliliter of 61% nitric acid, keep temperature of reaction not to be higher than 20 ℃ simultaneously, and at room temperature stirred 2 hours.After adding 200 milliliters of ethyl acetate, water, sodium bicarbonate aqueous solution, water and salt solution washing reaction mixture in succession, pressure reducing and steaming ethyl acetate.Resistates is purified with silica gel column chromatography, and chloroform-normal hexane (1: 1) is made elutriant, obtains 2.85 gram 2-nitrothymols.
In 50 milliliters of ethanolic solns of 2.85 gram 2-nitrothymols, add 0.28 gram 10% palladium-charcoal, fed hydrogen under the room temperature while stirring 4 hours.Leach palladium-charcoal, remove under reduced pressure and obtain the amino thymols of 2.41 gram crude product 2-behind the solvent.
The amino thymol of crude product 2-of dissolving 8.46 gram rifamycin-Ss and 2.41 gram gained in 200 milliliters of toluene stirred the mixture 14 hours under 50 ℃.Then by handling and the purified reaction mixture as embodiment 1 identical mode, obtain 4.0 grams required 3 '-methyl-6 '-sec.-propyl benzo oxazine rifomycin.
Thin-layer chromatography
Rf=0.25, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 60
(synthesizing of No. 45 derivative)
Dissolving 1.0 grams 3 in 5 milliliters of dimethyl alums '-methyl-6 '-add 0.17 milliliter of azetidine and 1.0 gram Manganse Dioxide behind the sec.-propyl benzo oxazine rifomycin, stirred the mixture under the room temperature 4 days.By the mode reaction mixture identical, draw No. 45 required derivative of 0.23 gram with embodiment 2.
Embodiment 61
(synthesizing of No. 46 derivative)
Except replacing azetidine with 0.52 milliliter of tetramethyleneimine and the reaction times being changed into two days by four days, repeat the operation steps of embodiment 60, obtain No. 46 required derivative of 0.22 gram.
Embodiment 62
(3 '-sec.-propyl-6 '-Jia base benzoxazine rifomycin synthetic)
In 100 milliliters of acetic acid solutions of 9.96 gram kind celery phenol, add 50 milliliters of acetic acid solutions that are dissolved with 4.96 milliliter of 61% nitric acid, keep temperature of reaction not to be higher than 20 ℃ simultaneously, stirred 5 hours under the room temperature.After adding 300 milliliters of ethyl acetate, water, sodium bicarbonate aqueous solution, water and salt solution washing reaction mixture remove ethyl acetate under reduced pressure successively.Resistates is purified through silica gel column chromatography, and chloroform-normal hexane (1: 2) is made elutriant, obtains 4.4 gram 2-nitro kind celery phenol.
In 80 milliliters of ethanolic solns of 4.4 gram 2-nitro kind celery phenol, add 0.44 gram 10% palladium-charcoal, fed hydrogen under the room temperature while stirring 5 hours.Leach palladium-charcoal, remove solvent under reduced pressure, obtain the amino kind celery phenol of 2.8 gram crude product 2-.
The amino kind celery phenol of crude product 2-of dissolving 9.82 gram rifamycin-Ss and 2.8 gram gained in 300 milliliters of toluene stirred the mixture 12 hours under 50 ℃.Then by handling and the purified reaction mixture as embodiment 1 identical mode, obtain 6.53 grams required 3 '-sec.-propyl-6 '-first base benzoxazine rifomycin.
Thin-layer chromatography
Rf=0.15, purple red color spot (carrier: silica gel, solvent system: chloroform-acetone (9: 1)).
Embodiment 63
(synthesizing of No. 47 derivative)
In 5 milliliters of dimethyl alums dissolving 1.0 grams press the operation steps synthetic 3 of embodiment 62 '-sec.-propyl-6 '-add 0.17 milliliter of azetidine and 1.0 behind the Jia base benzoxazine rifomycin to restrain Manganse Dioxide, stirred the mixture under the room temperature 3 days.By the mode reaction mixture identical, obtain No. 47 required derivative of 0.18 gram then with embodiment 2.
Embodiment 64
(synthesizing of No. 48 derivative)
Repeat the operation steps of embodiment 63 except replacing the azetidine, obtain No. 48 required derivative of 0.30 gram with 0.21 milliliter of tetramethyleneimine.
Embodiment 65
(synthesizing of No. 49 derivative)
Except with 0.60 milliliter
Pyridine replaces azetidine and the reaction times was changed into outside 24 hours by 3 days, repeats the operation steps of embodiment 63, obtains No. 49 required derivative of 0.57 gram.
Embodiment 66
(synthesizing of No. 50 derivative)
In 35 milliliters of ethanolic solns of No. 13 derivative of 1.0 grams, add 15 milliliter of 10% aqueous sodium hydroxide solution, stirred this mixture 1 hour under the room temperature.After adding 300 ml waters,, use anhydrous sodium sulfate drying with 500 milliliters of chloroform extraction reaction mixtures.Leach siccative, remove solvent under reduced pressure.Resistates is purified with silica gel column chromatography (ethyl acetate is made elutriant) method, and crystallization in ethyl acetate or hexane, draws No. 50 derivative of 0.57 gram.
Embodiment 67
(synthesizing of No. 51 derivative)
Except replace No. 13 derivative with No. 18 derivative of 0.85 gram, repeat operation steps among the embodiment 66, obtain No. 51 derivative of 0.31 gram.
Embodiment 68
(synthesizing of No. 52 derivative)
Except replace No. 13 derivative with No. 19 derivative of 1.0 grams, repeat the operation steps of embodiment 66, obtain No. 52 derivative of 0.19 gram.
Embodiment 69
(synthesizing of No. 53 derivative)
Except replace No. 13 derivative with No. 22 derivative of 1.73 grams, repeat operation steps among the embodiment 66, obtain No. 53 derivative of 1.02 grams.
Embodiment 70
(synthesizing of No. 54 derivative)
Except with No. 13 derivatives of No. 28 derivative replacement of 0.75 gram, repeat operation steps among the embodiment 66, obtain No. 54 derivative of 0.17 gram.
The composition that in these embodiment, uses,, also can use other composition in these embodiments for obtaining essentially identical result as setting forth in the specification sheets.
Claims (26)
1, a kind of Ryfamycin derivative (I) or its salt, said derivative (I) is:
In the formula: X
1Be the cycloalkyl of the alkyl or 3-8 the carbon atom of 1-6 carbon atom,
X
2It is the alkyl of a hydrogen atom or 1-5 carbon atom;
R
1Be hydrogen atom or ethanoyl;
A is by formula:
The group of representative, wherein: R
2Be the alkyl of 1-4 carbon atom or the alkoxyalkyl of 2-6 carbon atom, R
3Be the alkyl of 1-6 carbon atom or the alkoxyalkyl of 2-6 carbon atom,
Be the 3-9 unit's cyclammonium base and the R of 2-8 carbon atom of band
4It is the alkyl of a hydrogen atom or 1-3 carbon atom.
2, the Ryfamycin derivative of claim 1 or its salt, the wherein R in (I)
1It is hydrogen atom.
3, the Ryfamycin derivative of claim 1 or its salt, the wherein R in (I)
1It is ethanoyl.
4, the Ryfamycin derivative of claim 1 or its salt, the wherein X of (I)
1In be the cycloalkyl of the alkyl or 3-8 the carbon atom of 1-6 carbon atom.
5, the Ryfamycin derivative in the claim 1 or its salt, the wherein X in (I)
2It is the alkyl of a hydrogen atom or 1-5 carbon atom.
6, the Ryfamycin derivative of claim 1 or its salt, wherein: the A in (I) is by formula:
Or by formula:
The group of representative; R in the formula
2Be the alkyl of 1-3 carbon atom or the alkoxyalkyl of 2-6 carbon atom, R
3Be the alkyl of 1-6 carbon atom or the alkoxyalkyl of 2-6 carbon atom,
It is the 3-9 unit cyclammonium base of 2-8 carbon atom of band.
7, the Ryfamycin derivative of claim 1 or its salt, wherein: the A in (I) is by formula:
The group of representative, and R wherein
2Be the alkyl and the R of 1-3 carbon atom
3It is the alkyl of 1-6 carbon atom.
8, the Ryfamycin derivative of claim 1 or its salt, wherein: the A in (I) is by formula
The group of representative, wherein
Be the 3-9 unit cyclammonium base of 2-8 carbon atom of band, R
4It is the alkyl of a hydrogen atom or 1-3 carbon atom.
9, the Ryfamycin derivative of claim 1 or its salt, wherein on the phenylene ring C4 ' position in (I) by methyl substituted, R
1Be that ethanoyl and A are by formula:
The group of representative.
10, the Ryfamycin derivative of claim 1 or its salt, wherein on the phenylene ring C4 ' position in (I) by methyl substituted, R
1Be that ethanoyl and A are by formula:
The group of representative.
11, the Ryfamycin derivative of claim 1 or its salt, wherein on the phenylene ring C4 ' position in (I) by methyl substituted, R
1Be that ethanoyl and A are by formula:
The group of representative.
12, the Ryfamycin derivative of claim 1 or its salt, wherein on the C6 ' position of the phenylene ring in (I) by methyl substituted, R
1Be that ethanoyl and A are by formula:
The group of representative.
13, the Ryfamycin derivative of claim 1 or its salt are wherein replaced R on the phenylene ring C4 ' position in (I) by ethyl
1Be that ethanoyl and A are by formula:
The group of representative.
14, the Ryfamycin derivative of claim 1 or its salt are wherein replaced R on the phenylene ring C4 ' position in (I) by ethyl
1Be that ethanoyl and A are by formula:
The group of table.
15, the Ryfamycin derivative of claim 1 or its salt are wherein replaced R on the phenylene ring C6 ' position in (I) by ethyl
1Be that ethanoyl and A are by formula:
The group of representative.
16, the Ryfamycin derivative of claim 1 or its salt are wherein replaced R on the phenylene ring C6 ' position in (I) by ethyl
1Be that ethanoyl and A are by formula
The group of representative.
17, the Ryfamycin derivative of claim 1 or its salt, wherein the phenylene ring C4 ' position in (I) is replaced R by n-propyl
1Be that ethanoyl and A are by formula:
The group of representative.
18, the Ryfamycin derivative of claim 1 or its salt are wherein replaced R on the phenylene ring C4 ' position in (I) by n-propyl
1Be that ethanoyl and A are by formula:
The group of representative.
19, the Ryfamycin derivative of claim 1 or its salt are wherein replaced R by sec.-propyl on the C4 ' position in (I)
1Be that ethanoyl and A are by formula:
The group of representative.
20, the Ryfamycin derivative of claim 1 or its salt are wherein replaced R on the phenylene ring C4 ' position in (I) by normal-butyl
1Be that hydrogen atom and A are by formula:
The group of representative.
21, the Ryfamycin derivative of claim 1 or its salt are wherein replaced R on the phenylene ring C4 ' position in (I) by sec-butyl
1Be that ethanoyl and A are by formula:
The group of representative.
22, the Ryfamycin derivative of claim 1 or its salt, wherein on the phenylene ring C4 ' position in (I) and on C6 ' position all by methyl substituted, R
1Be that ethanoyl and A are by formula:
The group of representative.
23, a kind of method for preparing Ryfamycin derivative (I): said method comprises the amine reaction of the Ryfamycin derivative (II) that makes and general formula: AH:
In (I): X
1Be the cycloalkyl of the alkyl or 3-8 the carbon atom of 1-6 carbon atom,
X
2Be the alkyl of a hydrogen atom or 1-5 carbon atom,
R
1Be hydrogen atom or ethanoyl,
A is by formula:
The group of representative, wherein
R
2Be the alkyl of 1-4 carbon atom or the alkoxyalkyl of 2-6 carbon atom, and
R
3Be the alkyl of 1-6 carbon atom or the alkoxyalkyl of 2-6 carbon atom,
N is the 3-9 unit cyclammonium base of 2-8 carbon atom of band, and
R
4Be the alkyl of a hydrogen atom or 1-3 carbon atom,
X in (II)
1, X
2, R
1, the A definition among A and the AH as above.
24, the method for claim 23 wherein makes the amine reaction of Ryfamycin derivative (II) and formula: AH in the presence of oxygenant; In formula AH, A is by formula:
The group of representative, and R wherein
2Be the alkyl of 1-4 carbon atom or the alkoxyalkyl of 2-6 carbon atom, and R
3Be the alkyl of 1-6 carbon atom or the alkoxyalkyl of 2-6 carbon atom.
25, the method for claim 24, wherein said oxygenant is a Manganse Dioxide.
26, antiseptic-germicide wherein contains Ryfamycin derivative (I) or its salt as effective constituent, and said (I) is:
X in the formula
1Be the cycloalkyl of the alkyl or 3-8 the carbon atom of 1-6 carbon atom,
X
2Be the alkyl of a hydrogen atom or 1-5 carbon atom,
R
1Be hydrogen atom or ethanoyl,
A is by formula:
The group of representative, wherein R
2Be the alkyl of 1-4 carbon atom or the alkoxyalkyl of 2-6 carbon atom, and
R
3Be the alkyl of 1-6 carbon atom or the alkoxyalkyl of 2-6 carbon atom,
N is the 3-9 unit cyclammonium base of 2-8 carbon atom of band, and
R
4It is the alkyl of a hydrogen atom or 1-3 carbon atom.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP165121/86 | 1986-07-14 | ||
| JP16512186 | 1986-07-14 | ||
| JP243376/86 | 1986-10-14 | ||
| JP24337686 | 1986-10-14 | ||
| JP29436/87 | 1987-02-10 | ||
| JP2943687 | 1987-02-10 | ||
| JP62213/87 | 1987-03-17 | ||
| JP62062213A JP2544375B2 (en) | 1986-07-14 | 1987-03-17 | Alkyl-substituted benzoxazinorifamycin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN87104870A true CN87104870A (en) | 1988-02-17 |
| CN1018833B CN1018833B (en) | 1992-10-28 |
Family
ID=27459068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN87104870A Expired CN1018833B (en) | 1986-07-14 | 1987-07-14 | Alkyl-substituted benzoxazinorifamycin derivative, process for preparing same and antibacterial agent containing same |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4859661A (en) |
| EP (1) | EP0253340B1 (en) |
| JP (1) | JP2544375B2 (en) |
| CN (1) | CN1018833B (en) |
| CA (1) | CA1282780C (en) |
| DE (1) | DE3787586T2 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68924722T2 (en) * | 1988-03-18 | 1996-04-18 | Kanegafuchi Chemical Ind | Substituted benzoxazinorifamycin derivative, process for its preparation and bactericidal agents containing this derivative. |
| CA1304363C (en) * | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
| EP0861660B9 (en) * | 1997-02-28 | 2006-06-28 | Kaneka Corporation | Curative medicine for disease caused by infection of Helicobacter |
| AU2002368203A1 (en) * | 2001-09-06 | 2004-05-04 | Activbiotics, Inc. | Antimicrobial agents and uses thereof |
| US7122525B2 (en) * | 2001-11-21 | 2006-10-17 | Activbiotics, Inc. | Targeted therapeutics and uses thereof |
| US7078399B2 (en) * | 2001-12-13 | 2006-07-18 | Activbiotics, Inc. | Sulfhydryl rifamycins and uses thereof |
| US20090149453A1 (en) * | 2002-05-23 | 2009-06-11 | Activbiotics Pharma Llc | Methods and compositions for treating bacterial infections and diseases associated therewith |
| US20040077533A1 (en) * | 2002-05-23 | 2004-04-22 | Sayada Chalom B. | Methods and compositions for treating bacterial infections and diseases associated therewith |
| EP1531828A4 (en) * | 2002-05-23 | 2005-11-02 | Activbiotics Inc | Methods of treating bacterial infections and diseases associated therewith |
| AU2003296963A1 (en) * | 2002-12-12 | 2004-07-09 | Activbiotics, Inc. | Methods and compositions for treating and preventing ear infections |
| JP2006515294A (en) * | 2002-12-12 | 2006-05-25 | アクティブバイオティクス インコーポレイティッド | Methods and reagents for treating or preventing atherosclerosis and related diseases |
| EP1663107A4 (en) * | 2003-08-22 | 2010-06-23 | Activbiotics Pharma Llc | Rifamycin analogs and uses thereof |
| US7820652B2 (en) * | 2003-09-24 | 2010-10-26 | Activbiotics Pharma, Llc | Regimen for the administration of rifamycin-class antibiotics |
| WO2005058231A2 (en) * | 2003-12-10 | 2005-06-30 | Activbiotics, Inc. | Rifamycin analogs and uses thereof |
| CN1918172B (en) * | 2003-12-23 | 2011-09-14 | 活跃生物工艺学公司 | Rifamycin analogs and uses thereof |
| US7202246B2 (en) * | 2004-06-09 | 2007-04-10 | Cumbre Pharmaceuticals Inc. | Spiro-rifamycin derivatives targeting RNA polymerase |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| KR20160015286A (en) | 2013-05-31 | 2016-02-12 | 제넨테크, 인크. | Anti-wall teichoic antibodies and conjugates |
| CA2910029A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| KR20170086542A (en) | 2014-12-03 | 2017-07-26 | 제넨테크, 인크. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
| MX2017007055A (en) | 2014-12-03 | 2017-11-08 | Genentech Inc | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130099C (en) * | 1963-10-11 | |||
| US4690919A (en) * | 1984-01-04 | 1987-09-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
| JPS63183587A (en) * | 1985-02-05 | 1988-07-28 | Kanegafuchi Chem Ind Co Ltd | Benzoxazino-rifamycin derivative |
-
1987
- 1987-03-17 JP JP62062213A patent/JP2544375B2/en not_active Expired - Lifetime
- 1987-07-11 EP EP87110048A patent/EP0253340B1/en not_active Expired - Lifetime
- 1987-07-11 DE DE87110048T patent/DE3787586T2/en not_active Expired - Fee Related
- 1987-07-13 CA CA000542104A patent/CA1282780C/en not_active Expired - Lifetime
- 1987-07-13 US US07/075,021 patent/US4859661A/en not_active Expired - Lifetime
- 1987-07-14 CN CN87104870A patent/CN1018833B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CN1018833B (en) | 1992-10-28 |
| DE3787586T2 (en) | 1994-01-27 |
| JPS646279A (en) | 1989-01-10 |
| US4859661A (en) | 1989-08-22 |
| JP2544375B2 (en) | 1996-10-16 |
| CA1282780C (en) | 1991-04-09 |
| EP0253340A1 (en) | 1988-01-20 |
| DE3787586D1 (en) | 1993-11-04 |
| EP0253340B1 (en) | 1993-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN87104870A (en) | Benzoxazinnorifamyciderivative derivative, its preparation method that alkyl replaces and contain the antiseptic-germicide of this derivative | |
| CN1589258A (en) | Novel beta -phenyl- alpha -oxysubstituted propionic derivatives: process for their preparation and their use in the preparation of pharmaceutically important compounds | |
| CN1242983C (en) | Phenoxyacetic acid derivatives and medicinal compositions containing the same | |
| CN1610658A (en) | Processes for the preparation of glutamic acid compounds and intermediates thereof and novel intermediates used in the processes | |
| CN101050194A (en) | Derivative of bicyclo-octanes class, preparation method, and application of medicine | |
| CN1032751C (en) | Thiazolidine compound, preparing process thereof and its application in medicine | |
| CN87108160A (en) | Preparation and application have the method for the sialic acid derivative of active carbonyl group | |
| CN1033639C (en) | Benzoquinonyl-containing thiazolidine compound, preparing process thereof and its application in medicine | |
| CN1021819C (en) | Process for diurea derivatives useful as medicaments | |
| CN87100978A (en) | New Dihydrobenzofuranes-and chroman-carboxamide derivative and preparation method thereof and as the application of Antipsychotic drug | |
| CN1115337C (en) | Pyrimidinone derivs. | |
| CN1103534A (en) | Compound with antipsychotic effect | |
| CN1675144A (en) | Method for the separation of intermediates which may be used for the preparation of escitalopram | |
| CN1020104C (en) | Process for preparing cephene device | |
| CN1423637A (en) | Novel substituted tricyclic compounds | |
| CN1794997A (en) | 2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-5-carboxylic acid amide derivatives as gamma-secretase inhibitors for the treatment of alzheimer's disease | |
| CN1323300A (en) | An improved process for the preparation of new antidiabetic agents | |
| CN1152687C (en) | Crystalline trimetrexate salts and the process for making the same | |
| CN85101425A (en) | Have Si Baige Eyring allied compound of phenylene and preparation method thereof | |
| CN1041948A (en) | New this glucosides of B-D-phenyl sulfo-and preparation method thereof and therepic use | |
| CN1035827A (en) | The 4-oxo of opticity-1-chromene-2-carboxylic acid derivative and intermediates preparation thereof | |
| CN1039909C (en) | Aminobenzoic acid derivatives | |
| CN1261405C (en) | Optically active amine derivative and method of synthesis | |
| CN1112924A (en) | Novel thiazine or thiomorpholine derivatives | |
| CN1301244C (en) | Production method of (R)-3- hydroxy-3-(2-phenylethyl)hexanoic acid and intermediate thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C13 | Decision | ||
| C14 | Grant of patent or utility model | ||
| C19 | Lapse of patent right due to non-payment of the annual fee |